These include the 2013 ACC/ AHA CPGs on management of blood cholesterol,18 and the 2014 recommendations for management which were published during the develop- ment of this CPG. To provide the interventions and services listed in Table 10, appropriate resources must be used so that patients with MI have full access to evidence-based therapies and follow-up care. There is a growing emphasis on penalizing hospitals for avoidable hospital readmissions. It is imperative for health systems to work with clinicians, nurses, pharmacists, communities, payers, and public agencies to support the inter- ventions that achieve comprehensive care. Several patient char- acteristics have been predictors of readmission after AMI.502,503 7. Special Patient Groups See Table 11 for summary of recommendations for this section. 7.1. NSTE-ACS in Older Patients: Recommendations Class I 1. Older patients** with NSTE-ACS should be treated with GDMT, an early invasive strategy, and revascu- larization as appropriate.515 519 (Level of Evidence: A) 2. Pharmacotherapy in older patients** with NSTE- ACS should be individualized and dose adjusted by weight and/or CrCl to reduce adverse events caused by age-related changes in pharmacokinetics/dynam- ics, volume of distribution, comorbidities, drug inter- actions, and increased drug sensitivity.515,520 522 (Level of Evidence: A) 3. Management decisions for older patients** with NSTE-ACS should be patient centered, and consider patient preferences/goals, comorbidities, functional (Level of Evidence: B) Class IIa 1. Bivalirudin, rather than a GP IIb/IIIa inhibitor plus UFH, is reasonable in older patients** with NSTE- ACS, both initially and at PCI, given similar efficacy but less bleeding risk.396,526 528 (Level of Evidence: B) 2. 